A review of cytokine removal/hemoadsorption therapy
Hmmm… to a layman like myself, this seems to be a less than glowing report on cytokine hemoadsorption therapy. Sept 2018
Wonder if CTSO read this?
paging ST Tom. Why is the CTSO market cap > 9 times that of EDT again?
https://www.karger.com/Article/FullText/492379 “
Removal of anti-inflammatory cytokines may similarly lead to adverse effects in the setting of sepsis and critical illness…” “given the infancy of hemoadsorption therapy, a more appropriate approach may be careful parameter- or biomarker-directed patient selection for clinical trials. … could enable treatment to be more tailored to patients” If only some Company out there offered such an approach.
MM